SCHEMBL4281644

SCHEMBL4281644

Oc1cccc2[nH][c]cc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IMPDH2 P12268 1/20 0.41
IMPDH1 P20839 1/20 0.41
HPGD P15428 4/20 0.39
HSD17B10 Q99714 4/20 0.39
ALOX15 P16050 3/20 0.39
RECQL P46063 3/20 0.39
TDP1 Q9NUW8 3/20 0.39
CYP1A2 P05177 2/20 0.39
MAPT P10636 2/20 0.39
APP P05067 1/20 0.39
THRB P10828 1/20 0.39
TSHR P16473 1/20 0.39
CASP1 P29466 1/20 0.39
SNCA P37840 1/20 0.39
ALDH1A1 P00352 5/20 0.36
CA2 P00918 4/20 0.36
LMNA P02545 3/20 0.36
CA1 P00915 3/20 0.36
CA6 P23280 3/20 0.36
EGFR P00533 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4276905 0.73 CYP1A2 (0.46) CYP1A2TSHRLMNADAO
SCHEMBL442418 0.73 DAO (0.39) DAODDO
SCHEMBL539330 0.73 CYP1A2 (0.46) HPGDHSD17B10CYP1A2TSHRALDH1A1
SCHEMBL20562764 0.72 NR4A1 (0.48) HPGDHSD17B10ALOX15TSHRALDH1A1
SCHEMBL9739950 0.68 IMPDH2 (0.41) IMPDH2IMPDH1MAPTTSHRALDH1A1
SCHEMBL9739475 0.68 METAP2 (0.50) HPGDHSD17B10ALDH1A1CDK2KDM4E
SCHEMBL1243755 0.68 KIF11 (0.46) TDP1TSHRALDH1A1CA2
SCHEMBL1539240 0.68 ABCG2 (0.41) HPGDHSD17B10ALOX15MAPTALDH1A1
SCHEMBL4693055 0.68
SCHEMBL9739424 0.68 AXL (0.50) HPGDHSD17B10ALDH1A1CA2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7534793-B2 Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity SMITHKLINE BEECHAM P.L.C. (GB) 2009-05-19 US claimed
EP-1305308-B1 AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY SMITHKLINE BEECHAM PLC (GB) 2006-12-20 EP claimed
US-7534793-B2 Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity SMITHKLINE BEECHAM P.L.C. (GB) 2009-05-19 US disclosed
EP-1305308-B1 AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY SMITHKLINE BEECHAM PLC (GB) 2006-12-20 EP disclosed
US-20060014749-A1 Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity SMITHKLINE BEECHAM P.L.C. 2006-01-19 US disclosed
US-6962917-B2 Aminopiperidine quinolines and their azaisosteric analogues with antibacterical activity SMITHKLINE BEECHAM P.L.C. (GB) 2005-11-08 US disclosed
EP-1305308-A1 AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY SMITHKLINE BEECHAM PLC (GB) 2003-05-02 EP disclosed
WO-2002008224-A1 AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY SMITHKLINE BEECHAM P.L.C. (GB) 2002-01-31 WO disclosed
US-5175157-A Cardiovascular disorders BOEHRINGER INGELHEIM GMBH (DE) 1992-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014749-A1 Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity AZI2, NPEPPS, AMPD2 IMPDH2 82/4885IMPDH1 33/4885HPGD 1193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.